These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21502616)

  • 21. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
    J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum.
    Britt NS; Hazlett DS; Horvat RT; Liesman RM; Steed ME
    Int J Antimicrob Agents; 2020 Apr; 55(4):105898. PubMed ID: 31931147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE; Fallon M; Moran JJ; Vanderloo JP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility pattern of methicillin resistant Staphylococcus aureus to vancomycin and other alternate agents: report from a private sector hospital laboratory.
    Saleem F; Fasih N; Zafar A
    J Pak Med Assoc; 2017 Nov; 67(11):1743-1746. PubMed ID: 29171572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
    Uçkay I; Bernard L; Buzzi M; Harbarth S; François P; Huggler E; Ferry T; Schrenzel J; Renzoni A; Vaudaux P; Lew DP
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1258-64. PubMed ID: 22155824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
    Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T
    Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonistic Effect of Colistin on Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus in
    Choi S; Moon SM; Park SJ; Lee SC; Jung KH; Sung HS; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.
    Edwards B; Milne K; Lawes T; Cook I; Robb A; Gould IM
    J Clin Microbiol; 2012 Feb; 50(2):318-25. PubMed ID: 22135252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
    Honda H; Doern CD; Michael-Dunne W; Warren DK
    BMC Infect Dis; 2011 Dec; 11():335. PubMed ID: 22142287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.
    Mascitti KB; Edelstein PH; Fishman NO; Morales KH; Baltus AJ; Lautenbach E
    Infect Control Hosp Epidemiol; 2012 Feb; 33(2):160-6. PubMed ID: 22227985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An investigation of vancomycin minimum inhibitory concentration creep among methicillin-resistant Staphylococcus aureus strains isolated from pediatric patients and healthy children in Northern Taiwan.
    Chang CN; Lo WT; Chan MC; Yu CM; Wang CC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):362-369. PubMed ID: 26297168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.